# Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)

> **NCT06681285** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 51 (estimated)

## Conditions studied

- Esophageal Carcinoma

## Interventions

- **DRUG:** Cadonilimab ;Anlotinib

## Key facts

- **NCT ID:** NCT06681285
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06681285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06681285, "Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06681285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*